Increasing evidence indicates that NSCLC patients exhibit higher EGFR levels and they may have a lower risk of BM if EGFR inhibitors (e.g., gefitinib) are introduced in the treatment (12). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.